Exome Asset Management LLC — 13F Holdings & Portfolio
CIK 2011932 · latest 13F-HR filed 2026-08-14
Exome Asset Management LLC manages $162.1M in 13F-reported U.S. long-equity assets across 52 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are GH (6.25%), PRAX (5.62%), TGTX (5.59%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 15 new positions and exited 8; 9 existing positions rose in reported value and 24 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 44.6%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Mar 27, 2026.
SUITE 3010
NEW YORK, NY 10017
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| FORSCHNER, ALEX, R Control | PRESIDENT since Sep 2023 | 10–25% | Individual |
| ISALY, SAMUEL, DAVID Control | MANAGING MEMBER since May 2018 | 75% or more | Individual |
| NARVAEZ, JOSEPH, A Control | CHIEF OPERATING OFFICER since Sep 2023 | 10–25% | Individual |
| SHERGILL, BRIANNE Control | CHIEF COMPLIANCE OFFICER since Oct 2022 | Less than 5% | Individual |
Ownership & leadership changes · 5 filings with changes since Aug 28, 2019
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- AddedNARVAEZ, JOSEPH, A · CHIEF OPERATING OFFICER · 10–25% · control person
- Listed againFORSCHNER, ALEX, R · PRESIDENT · 10–25% · control person
- No longer listedFORSCHNER, ALEX, R · CHIEF COMPLIANCE OFFICER / HEAD OF BUSINESS DEVELOPMENT · Less than 5% · listed since Aug 2022
- AddedSHERGILL, BRIANNE · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
- No longer listedHagen, Meredith, Sue · CHIEF COMPLIANCE OFFICER · Less than 5% · listed since Jun 2021
- AddedFORSCHNER, ALEX, R · CHIEF COMPLIANCE OFFICER / HEAD OF BUSINESS DEVELOPMENT · Less than 5%
- ChangedISALY, SAMUEL, DAVID · title MEMBER → MANAGING MEMBER
- AddedHagen, Meredith, Sue · CHIEF COMPLIANCE OFFICER · Less than 5%
- ListedISALY, SAMUEL, DAVID · MEMBER · 75% or more · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- GUARDANT HEALTH INC$2.5M +32.5%
- LIQUIDIA CORPORATION$1.4M +80.9%
- MAZE THERAPEUTICS INC$780.4K +29.5%
- 10X GENOMICS INC$661.3K +20.2%
- GLAUKOS CORP$528.6K +23.5%
Top Trims
- PRAXIS PRECISION MEDICINES I-$5.5M -37.8%
- BRIDGEBIO PHARMA INC-$3.6M -72.7%
- ENLIVEN THERAPEUTICS INC-$3.5M -41.1%
- INSMED INC-$2.9M -66.1%
- COGENT BIOSCIENCES INC-$2.6M -24.0%
New Positions
- TG THERAPEUTICS INC$9.1M
- ABIVAX SA$6.2M
- UNIQURE NV$3.7M
- ASTRAZENECA PLC$2.3M
- VIKING THERAPEUTICS INC$1.9M
Exited Positions
- ELEVANCE HEALTH INC FORMERLY$4.3M
- APELLIS PHARMACEUTICALS INC$3.4M
- AVALO THERAPEUTICS INC$2.4M
- SOLENO THERAPEUTICS INC$2.1M
- 4D MOLECULAR THERAPEUTICS IN$1.2M
Exome Asset Management LLC Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | GUARDANT HEALTH INC | GH | 40131M109 | $10.1M | 6.25% | 67,500 | SH |
| 2 | PRAXIS PRECISION MEDICINES I | PRAX | 74006W207 | $9.1M | 5.62% | 27,205 | SH |
| 3 | TG THERAPEUTICS INC | TGTX | 88322Q108 | $9.1M | 5.59% | 164,915 | SH |
| 4 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $8.1M | 5.03% | 210,523 | SH |
| 5 | IONIS PHARMACEUTICALS INC | IONS | 462222100 | $7.0M | 4.31% | 88,177 | SH |
| 6 | ELI LILLY & CO | LLY | 532457108 | $6.6M | 4.06% | 5,492 | SH |
| 7 | ABIVAX SA | ABVX | 00370M103 | $6.2M | 3.85% | 46,878 | SH |
| 8 | ALUMIS INC | ALMS | 022307102 | $5.8M | 3.55% | 204,418 | SH |
| 9 | CYTOKINETICS INC | CYTK | 23282W605 | $5.1M | 3.16% | 60,056 | SH |
| 10 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $5.1M | 3.14% | 100,203 | SH |
| 11 | VERA THERAPEUTICS INC | VERA | 92337R101 | $4.2M | 2.57% | 97,276 | SH |
| 12 | UNITEDHEALTH GROUP INC | UNH | 91324P102 | $4.0M | 2.46% | 9,612 | SH |
| 13 | 10X GENOMICS INC | TXG | 88025U109 | $3.9M | 2.43% | 102,629 | SH |
| 14 | NATERA INC | NTRA | 632307104 | $3.7M | 2.31% | 13,800 | SH |
| 15 | UNIQURE NV | QURE | N90064101 | $3.7M | 2.30% | 81,056 | SH |
| 16 | RHYTHM PHARMACEUTICALS INC | RYTM | 76243J105 | $3.6M | 2.21% | 32,209 | SH |
| 17 | MAZE THERAPEUTICS INC | MAZE | 578784100 | $3.4M | 2.11% | 114,692 | SH |
| 18 | MONTE ROSA THERAPEUTICS INC | GLUE | 61225M102 | $3.3M | 2.05% | 137,115 | SH |
| 19 | MOONLAKE IMMUNOTHERAPEUTICS | MLTX | 61559X104 | $3.2M | 2.00% | 166,493 | SH |
| 20 | ALKERMES PLC | ALKS | G01767105 | $3.2M | 1.98% | 61,336 | SH |
| 21 | LIQUIDIA CORPORATION | LQDA | 53635D202 | $3.1M | 1.93% | 39,224 | SH |
| 22 | UNITED THERAPEUTICS CORP DEL | UTHR | 91307C102 | $2.9M | 1.81% | 5,410 | SH |
| 23 | GLAUKOS CORP | GKOS | 377322102 | $2.8M | 1.71% | 19,862 | SH |
| 24 | ARROWHEAD PHARMACEUTICALS IN | ARWR | 04280A100 | $2.6M | 1.62% | 32,214 | SH |
| 25 | AGIOS PHARMACEUTICALS INC | AGIO | 00847X104 | $2.6M | 1.61% | 70,500 | SH |
| 26 | CRESCENT BIOPHARMA INC. | CBIO | G2545C104 | $2.3M | 1.42% | 127,769 | SH |
| 27 | ASTRAZENECA PLC | AZN | G0593M107 | $2.3M | 1.39% | 12,045 | SH |
| 28 | BOSTON SCIENTIFIC CORP | BSX | 101137107 | $2.1M | 1.27% | 48,347 | SH |
| 29 | ADAGENE INC | ADAG | 005329107 | $2.1M | 1.27% | 488,293 | SH |
| 30 | PENUMBRA INC | PEN | 70975L107 | $2.0M | 1.23% | 6,300 | SH |
| 31 | INTUITIVE SURGICAL INC | ISRG | 46120E602 | $2.0M | 1.20% | 4,908 | SH |
| 32 | VIKING THERAPEUTICS INC | VKTX | 92686J106 | $1.9M | 1.15% | 47,861 | SH |
| 33 | OCULAR THERAPEUTIX INC | OCUL | 67576A100 | $1.8M | 1.10% | 181,588 | SH |
| 34 | EQUILLIUM INC | EQ | 29446K106 | $1.8M | 1.09% | 552,956 | SH |
| 35 | ASCENDIS PHARMA A/S | ASND | K08588103 | $1.8M | 1.08% | 6,573 | SH |
| 36 | CORBUS PHARMACEUTICALS HLDGS | CRBP | 21833P301 | $1.7M | 1.07% | 184,914 | SH |
| 37 | CYTOMX THERAPEUTICS INC. | CTMX | 23284F105 | $1.7M | 1.06% | 460,067 | SH |
| 38 | VERASTEM INC | VSTM | 92337C203 | $1.6M | 1.01% | 429,041 | SH |
| 39 | NEKTAR THERAPEUTICS | NKTR | 640268306 | $1.6M | 0.97% | 22,417 | SH |
| 40 | CLEARPOINT NEURO INC | CLPT | 18507C103 | $1.5M | 0.92% | 83,636 | SH |
| 41 | INSMED INC | INSM | 457669307 | $1.5M | 0.91% | 13,873 | SH |
| 42 | CARIS LIFE SCIENCES INC | CAI | 142152107 | $1.4M | 0.86% | 78,180 | SH |
| 43 | BRIDGEBIO PHARMA INC | BBIO | 10806X102 | $1.4M | 0.84% | 18,359 | SH |
| 44 | ZENAS BIOPHARMA INC | ZBIO | 98937L105 | $1.3M | 0.82% | 52,443 | SH |
| 45 | NOVABRIDGE BIOSCIENCES | NBP | 44975P103 | $1.1M | 0.69% | 576,960 | SH |
| 46 | ESTABLISHMENT LABS HLDGS INC | ESTA | G31249108 | $1.1M | 0.69% | 13,100 | SH |
| 47 | RELAY THERAPEUTICS INC | RLAY | 75943R102 | $889.3K | 0.55% | 47,531 | SH |
| 48 | GERON CORP | GERN | 374163103 | $798.8K | 0.49% | 624,046 | SH |
| 49 | BRIGHT MINDS BIOSCIENCES INC | DRUG | 10919W405 | $709.7K | 0.44% | 10,110 | SH |
| 50 | COMPASS THERAPEUTICS INC | CMPX | 20454B104 | $604.8K | 0.37% | 276,165 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $162.1M | 52 | 0001420506-26-001714 |
| 2026-03-31 | 2026-05-15 | $193.3M | 56 | 0001420506-26-001033 |
| 2025-12-31 | 2026-02-13 | $209.1M | 60 | 0001420506-26-000376 |
| 2025-09-30 | 2025-11-14 | $165.1M | 68 | 0001420506-25-003369 |
NEW YORK, NY 10017